Treatment News : New Look at Failed 2009 Vaccine Study Yields Promising Leads

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » January 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

January 18, 2013

New Look at Failed 2009 Vaccine Study Yields Promising Leads

Further study into the sole HIV vaccine trial to demonstrate moderate effectiveness has yielded new findings that may point to a future vaccine when combined with other recent scientific discoveries, PlusNews.org reports. Publishing their paper in the journal Immunity, researchers from Duke University, the Thailand Ministry of Public Health and the U.S. Military HIV Research Program studied data from the six-year vaccine trial in Thailand called RV144. This study of 16,000 HIV-negative adults, whose results were released in 2009, showed that the investigatory vaccine reduced infection rates by 31 percent, which was short of the minimum 50 percent effectiveness epidemiologists say is needed to turn the tide of the epidemic.

According to the new study, the vaccine prompted four separate antibodies to mark the virus on a key site on the surface of HIV-infected cells. These indications alerted the so-called “killer T-cells” to attack and kill the infected cells. However, the researchers have stated that they cannot be sure this reaction was the cause of what protection the vaccine did provide against infection. Still, when added to the recent discovery that the immune system’s “broadly neutralizing antibodies” can effectively target the virus, this new understanding of the body’s natural defense mechanisms may one day contribute to the development of a more comprehensive, complex and ultimately effective vaccine.

To read the PlusNews.org story, click here.

To read the study abstract, click here.

Search: HIV, vaccine, PlusNews.org, Duke University, Thailand Ministry of Public Health, U.S. Military HIV Research Program, RV144, killer T-cells, broadly neutralizing antibodies.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (1 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV 101
HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
Disclosing Your Status
Starting Treatment
Search for the Cure
POZ Stories
POZ TV
Read the Blogs
Visit the Forums
Women
African American
Latino
Providers
Job Listings
Events Calendar


    guycmh328
    Columbus
    Ohio


    RyGuy00
    New York
    New York


    TaintedloveDC
    Washington
    DC


    jap022964
    el dorado
    Arkansas
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Can social media help stop HIV stigma?
Yes
No

Survey
Mind Matters

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.